Skip Ribbon Commands
Skip to main content
SharePoint

References

1. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php. Updated 2014. Accessed May 1, 2014.

2. Ialomiteanu AR, Hamilton H, Adlaf E, Mann RE. CAMH Monitor eReport 2015: Substance use, Mental Health and Well-being among Ontario Adults. Toronto, Ontario: Centre for Addiction and Mental Health; 2016. http://www.camh.ca/en/research/news_and_publications/CAMH%20Monitor/CAMH-Monitor-2015-eReport-Final-Web.pdf.

3. Boak A, Hamilton HA, Adlaf EM, Mann RE. Drug use among Ontario Students, 1977-2015: Detailed OSDUHS Findings. Toronto, Ontario: Centre for Addiction and Mental Health; 2015.

4. Health Canada. Summary of Results Canadian Student Tobacco, Alcohol and Drugs Survey 2014-15. http://healthycanadians.gc.ca/science-research-sciences-recherches/data-donnees/cstads-ectade/summary-sommaire-2014-15-eng.php. Updated 2016. Accessed 01/07, 2015.

5. Adlaf EM, Demers A, Gliksman L. Canadian Campus Survey 2004. Toronto, ON: Centre for Addiction and Mental Health; 2005.

6. American College Health Association. National College Health Assessment II: Ontario Province Reference Group Data Report. Hanover, MD: American College Health Association; 2013. http://www.cacuss.ca/_Library/Provincial_Reports/NCHA-II_WEB_SPRING_2013_ONTARIO_PROVINCE_REFERENCE_GROUP_DATA_REPORT.pdf.

7. Mammen G, Rehm J, Rueda S. Vaporizing Cannabis through E-Cigarettes: Prevalence and Socio-Demographic Correlates among Ontario High School Students. Can J Public Health. 2016;107(3):e337-e338.

8. Chiefs of Ontario. First Nations Regional Health Survey (RHS) Ontario Region Phase 2 (2008/2010): People's Report. Toronto, ON: Chiefs of Ontario; 2014. http://health.chiefs-of-ontario.org/sites/default/files/files/RHS%20Phase%202%20-%20Peoples%20Report.pdf.

9. First Nations Information Governance Centre, Chiefs of Ontario. First Nations Regional Health Survey (RHS) Phase 2 (2008/2010): Ontario Region Report on the Adult, Youth and Children Living in First Nations Communities. Ottawa, ON: Chiefs of Ontario; 2012. http://health.chiefs-of-ontario.org/sites/default/files/files/First%20Nations%20Regional%20Health%20Survey%20%28RHS%29%20Phase%202%20%2808-10%29%20Ontario%20Region%20Final%20Report%2012nov01v8.pdf.

10. Hamilton HA, van der Maas M, Boak A, Mann RE. Subjective Social Status, Immigrant Generation, and Cannabis and Alcohol use among Adolescents. J Youth Adolesc. 2014;43(7):1163-1175.

11. Khandor E, Mason K. The Street Health Report 2007. Toronto, ON: Street Health; 2007. http://www.streethealth.ca/downloads/the-street-health-report-2007.pdf.

12. Grinman MN, Chiu S, Redelmeier DA, et al. Drug Problems among Homeless Individuals in Toronto, Canada: Prevalence, Drugs of Choice, and Relation to Health Status. BMC Public Health. 2010;10(94).

13. Caldwell J. Substance use in Toronto: Trends and Current Issues. Toronto, ON: Toronto Public Health for TO Urban Health Fund Review Panel; 2015. http://www.toronto.ca/legdocs/mmis/2015/hf/bgrd/backgroundfile-78564.pdf.

14. Barnaby L, Penn R, Erickson PG. Drugs, Homelessness & Health: Homeless Youth Speak Out about Harm Reduction - the Shout Clinic Harm Reduction Report. Toronto, ON: Shout Clinic; 2010. http://www.wellesleyinstitute.com/wp-content/uploads/2010/02/homelessyouthspeakout_shoutclinic2010_v2.pdf.

15. Belle-Isle L, Walsh Z, Callaway R, et al. Barriers to Access for Canadians Who use Cannabis for Therapeutic Purposes. Int J Drug Policy. 2014;25(4):691-699.

16. Abacus Data. Medical Marijuana and Pharmacists: A National Survey of Canadians on their Perceptions and Attitudes Towards Marijuana. Ottawa, ON; 2016. https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/Abacus-CPhA_Feb2016_MedicalMarijuana.pdf.

17. Leonard L, Germain A. Ontario Harm Reduction Distribution Program: Final Outcome Evaluation. Ottawa, ON: Ontario Harm Reduction Distribution Program; 2009.

18. Public Health Agency of Canada. I-Track: Enhanced Surveillance of HIV, Hepatitis C and Associated Risk Behaviours among People Who Inject Drugs in Canada. Phase 2 Report. Ottawa: Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada; 2014. http://www.dal.ca/content/dam/dalhousie/pdf/Diff/gahps/PHAC%20ITrack-EN-FINAL_2014.pdf.

19. Woodall KL, Chow BLC, Lauwers A, Cass D. Toxicological Findings in Fatal Motor Vehicle Collisions in Ontario, Canada: A One-Year Study. J Forensic Sci. 2015;60(3):669-674.

20. Mann RE, Stoduto G, Ialomiteanu A, Asbridge M, Smart RG, Wickens CM. Self-Reported Collision Risk Associated with Cannabis use and Driving After Cannabis use among Ontario Adults. Traffic Inj Prev. 2010;11(2):115-122.

21. Sayer G, Ialomiteanu A, Stoduto G, et al. Increased Collision Risk among Drivers Who Report Driving After using Alcohol and After using Cannabis. Can J Public Health. 2014;105(1):e92-3.

22. Fischer B, Rodopoulos J, Rehm J, Ivsins A. Toking and Driving: Characteristics of Canadian University Students Who Drive After Cannabis use - an Exploratory Pilot Study. Drugs Educ Prev Policy. 2006;13(2):179-187.

23. Statistics Canada. Mental Health Profile, Canadian Community Health Survey - Mental Health. Ottawa, ON: Statistics Canada; 2013. http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1051101&p2=17.

24. Callaghan RC, Macdonald SA. Changes in the Rates of Alcohol- and Drug-Related Hospital Separations for Canadian Provinces: 1996 to 2005. Can J Public Health. 2009;100(5):393-396.

25. Drug and Alcohol Treatment Information System (DATIS). Substance Abuse Statistical Tables: Fiscal Year 2007/2008 to Fiscal Year 2012/2013. Toronto, ON: Centre for Addiction and Mental Health; 2013. http://www.datis.ca/pub/reports/SA%20Statistical%20Tables%20FY1213.pdf.

26. Cairney J, Gandhi S, Guttmann A, et al. The Mental Health of Children and Youth in Ontario: A Baseline Scorecard. Toronto, ON: Institute for Clinical Evaluative Sciences; 2015.

27. Gomes T, Paterson JM, Caetano P, Sketris I, Henry D. CNODES Analysis: Safety of Oral Opioid use in Canada. Part 1: Changes in the Dispensing of Oral Opioid Drugs in Canadian Provinces between 2008 and the End of 2013. Canadian Network for Observational Drug Effect Studies (CNODES); 2015. https://www.researchgate.net/publication/279204495_CNODES_analysis_Safety_of_oral_Opioid_use_in_Canada_Part_1_Changes_in_the_dispensing_of_oral_opioid_drugs_in_Canadian_provinces_between_2008_and_the_end_of_2013.

28. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of Opioid Analgesics and Related Mortality before and After the Introduction of Long-Acting Oxycodone. CMAJ. 2009;181(12):891-896.

29. Fischer B, Murphy Y, Jones W, Ialomiteanu A, Rehm J. Recent Developments in Prescription Opioid-Related Dispensing and Harm Indicators in Ontario, Canada. Pain Physician. 2015;18(4):E659-E662.

30. Fischer B, Jones W, Rehm J. Trends and Changes in Prescription Opioid Analgesic Dispensing in Canada 2005-2012: An Update with a Focus on Recent Interventions. BMC Health Serv Res. 2014;14(1):90.

31. The Ontario Drug Policy Research Network. Opioid use and Related Adverse Events in Ontario. Toronto, ON: The Ontario Drug Policy Research Network; 2016. http://odprn.ca/wp-content/uploads/2016/11/ODPRN-Opioid-Use-and-Related-Adverse-Events-Nov-2016.pdf.

32. Patented Medicine Prices Review Board (PMPRB). Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13. Ottawa, Ontario: Patented Medicine Prices Review Board (PMPRB); 2014. http://www.pmprb-cepmb.gc.ca/CMFiles/NPDUIS/NPDUIS_Opiods_2014-04-16_EN_V2.pdf.

33. Shield KD, Jones W, Rehm J, Fischer B. Use and Nonmedical use of Prescription Opioid Analgesics in the General Population of Canada and Correlations with Dispensing Levels in 2009. Pain Res Manag. 2013;18(2):69-74.

34. Health Canada. Non-Insured Health Benefits Ontario Region Prescription Drug Trends: A Ten-Year Analysis. Ottawa Ontario: Health Canada; 2010.

35. Turner S, Gomes T, Camacho X, et al. Neonatal Opioid Withdrawal and Antenatal Opioid Prescribing. CMAJ. 2015;3(1):E55-E61.

36. Popova S, Patra J, Mohapatra S, Fischer B, Rehm J. How Many People in Canada use Prescription Opioids Non-Medically in General and Street Drug using Populations? Can J Public Health. 2009;100(2):104-108.

37. Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): A National Survey of Canadians' use of Alcohol and Other Drugs: Prevalence of use and Related Harms: Detailed Report. Ottawa, ON: Canadian Centre on Substance Abuse; 2005.

38. Smylie J, Firestone M, Cochran L, et al. Our Health Counts: Urban Aboriginal Health Database Research Project. Community Report. First Nations Adults and Children. Hamilton, Ontario: Our Health Counts Governing Council; 2011.

39. Kanate D, Folk D, Cirone S, et al. Community-Wide Measures of Wellness in a Remote First Nations Community Experiencing Opioid Dependence: Evaluating Outpatient Buprenorphine-Naloxone Substitution Therapy in the Context of a First Nations Healing Program. Can Fam Physician. 2015;61(2):160-165.

40. Wabasse L, Katt M. OxyContin Change and Impact on NAN First Nations: Briefing Note. Thunder Bay, ON: Nishnawbe Aski Nation (NAN); 2012. http://apihtawikosisan.com/wp-content/uploads/2012/02/BN-on-OxyNeo-mklw-v9-final.pdf.

41. Fischer B, Rehm J, Patra J, Firestone Cruz M. Changes in Illicit Opioid use Profiles Across Canada. CMAJ. 2006;175(11):1385-1387.

42. Millson P, Challacombe L, Villeneue PJ, et al. Reduction in Injection-Related HIV Risk After 6 Months in a Low-Threshold Methadone Treatment Program. AIDS Educ Prev. 2007;19(2):124-136.

43. Johnson S, MacDonald SF, Cheverie M, Myrick C, Fischer B. Prevalence and Trends of Non-Medical Opioid and Other Drug use Histories among Federal Correctional Inmates in Methadone Maintenance Treatment in Canada. Drug Alcohol Depend. 2012;124(1-2):172-176.

44. Kouyoumdjian FG, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use Prior to Incarceration and Associated Socio-Behavioural Factors among Males in a Provincial Correctional Facility in Ontario, Canada. Can J Public Health. 2014;105(3):e198-202.

45. Ordean A, Kahan M, Graves L, Abrahams R, Boyajian T. Integrated Care for Pregnant Women on Methadone Maintenance Treatment: Canadian Primary Care Cohort Study. Can Fam Physician. 2013;59(10):e462-9.

46. Ordean A, Kahan M. Comprehensive Treatment Program for Pregnant Substance Users in a Family Medicine Clinic. Can Fam Physician. 2011;57(11):e430-5.

47. Balfour-Boehm J, Rea S, Gordon J, Dooley J, Kelly L, Robinson A. The Evolving Nature of Narcotic use in Northwestern Ontario. Can J Rural Med. 2014;19(4):158-160.

48. Kelly L, Guilfoyle J, Dooley J, et al. Incidence of Narcotic Abuse during Pregnancy in Northwestern Ontario: Three-Year Prospective Cohort Study. Can Fam Physician. 2014;60(10):493-498.

49. Fischer B, Patra J, Firestone Cruz M, Gittins J, Rehm J. Comparing Heroin Users and Prescription Opioid Users in a Canadian Multi-Site Population of Illicit Opioid Users. Drug Alcohol Rev. 2008;27(6):625-632.

50. Sankey C, Setnik B, Harsanyi Z, Michalko K, Yang Z, Geoffroy P. Opioid use Following the Introduction of an Extended-Release Oxycodone Formulation with Tamper-Resistant Properties: Prospective Historical Chart Review in Methadone-Maintained Patients. J Opioid Manag. 2016;12(2):149-159.

51. Hunter C, Strike C, Barnaby L, et al. Reducing Widespread Pipe Sharing and Risky Sex among Crystal Methamphetamine Smokers in Toronto: Do Safer Smoking Kits have a Potential Role to Play? Harm Reduct J. 2012;9:9.

52. Gomes T, Juurlink D, Yao Z, et al. Impact of Legislation and a Prescription Monitoring Program on the Prevalence of Potentially Inappropriate Prescriptions for Monitored Drugs in Ontario: A Time Series Analysis. CMAJ Open. 2014;2(4):256-261.

53. Kurdyak P, Gomes T, Yao Z, et al. Use of Other Opioids during Methadone Therapy: A Population-Based Study. Addiction. 2012;107(4):776-780.

54. Gomes T, Paterson JM, Juurlink DN, Dhalla IA, Mamdani MM. Reformulation of Controlled-Release Oxycodone and Pharmacy Dispensing Patterns Near the US-Canada Border. Open Med. 2012;6(4):141-145.

55. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN. Clustering of Opioid Prescribing and Opioid-Related Mortality among Family Physicians in Ontario. Can Fam Physician. 2011;57(3):e92-e96.

56. Patel T, Chang F, Mohammed HT, et al. Knowledge, Perceptions and Attitudes Toward Chronic Pain and its Management: A Cross-Sectional Survey of Frontline Pharmacists in Ontario, Canada. PLoS One. 2016;11(6):e0157151.

57. Gomes T, Redelmeier D, Juurlink D, Dhalla I, Camacho X, Mamdani M. Opioid Dose and Risk of Road Trauma in Canada: A Population-Based Study. JAMA Intern Med. 2013;173(3):196-201.

58. Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The Burden of Premature Opioid-Related Mortality. Addiction. 2014;109(9):1482-1488.

59. Ratnasingham S, Cairney J, Rehm J, Manson H, Kurdyak P. Opening Eyes, Opening Minds: The Ontario Burden of Mental Illness and Addictions Report. Toronto, ON: Institute for Clinical Evaluative Sciences and Public Health Ontario; 2012. http://www.offordcentre.com/docs/Opening%20Eyes.pdf.

60. CBC News. Record number of Ontario fentanyl deaths in 2015, new data from chief coroner's office shows. CBC News. September 24, 2016. Available from: http://www.cbc.ca/news/canada/toronto/record-number-of-ontario-fentanyl-deaths-in-2015-new-data-from-chief-coroner-s-office-shows-1.3777808.

61. Fischer B, Jones W, Urbanoski K, Skinner R, Rehm J. Correlations between Prescription Opioid Analgesic Dispensing Levels and Related Mortality and Morbidity in Ontario, Canada, 2005-2011. Drug Alcohol Rev. 2014;33(1):19-26.

62. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of Opioid-Users Whose Death was Related to Opioid-Toxicity: A Population-Based Study in Ontario, Canada. PLoS One. 2013;8(4):e60600.

63. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in Opioid use and Dosing among Socio-Economically Disadvantaged Patients. Open Med. 2011;5(1):e13-e22.

64. Leece P, Cavacuiti C, Macdonald EM, et al. Predictors of Opioid-Related Death during Methadone Therapy. J Subst Abuse Treat. 2015;57:30-35.

65. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and Emergency Department Visits due to Opioid Poisoning in Canada. Ottawa, ON: CIHI; 2016. https://secure.cihi.ca/free_products/Opioid%20Poisoning%20Report%20%20EN.pdf.

66. Expert Working Group on Narcotic Addiction. The Way Forward: Stewardship for Prescription Narcotics in Ontario. Ontario: Ontario Ministry of Health and Long-Term Care; 2012.

67. Ontario Drug Policy Research Network. Opioid Prescribing and Opioid-Related Hospital Visits in Ontario. Toronto, ON; 2016. http://c.ymcdn.com/sites/www.alphaweb.org/resource/collection/822EC60D-0D03-413E-B590-AFE1AA8620A9/FINAL_UPDATED_Opioid_Hosp_Report__March_2016.pdf. Accessed March 2016.

68. Fischer B, Rehm J, Brissette S, et al. Illicit Opioid use in Canada: Comparing Social, Health and Drug use Characteristics of Untreated Users in Five Cities (OPICAN Study). J Urban Health. 2005;82(2):250-266.

69. Ministry of Health and Long Term Care Ontario. Strategy to Prevent Opioid Addiction and Overdose. Toronto, ON: Ministry of Health and Long Term Care Ontario; 2016. https://news.ontario.ca/mohltc/en/2016/10/strategy-to-prevent-opioid-addiction-and-overdose.html.

70. Fischer B, Kurdyak P, Goldner E, Tyndall M, Rehm J. Treatment of Prescription Opioid Disorders in Canada: Looking at the 'Other Epidemic'? Subst Abuse Treat Prev Policy. 2016;11:12.

71. Zaric GS, Brennan AW, Varenbut M, Daiter JM. The Cost of Providing Methadone Maintenance Treatment in Ontario, Canada. Am J Drug Alcohol Abuse. 2012;38(6):559-566.

72. Pirie T, National Treatment Indicators Working Group. National Treatment Indicators Report: 2012–2013 Data. Ottawa, ON: Canadian Centre on Substance Abuse; 2015.

73. Bawor M, Dennis BB, Varenbut M, et al. Sex Differences in Substance use, Health, and Social Functioning among Opioid Users Receiving Methadone Treatment: A Multicenter Cohort Study. Biol Sex Differ. 2015;6:21.

74. Naji L, Dennis BB, Bawor M, et al. A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid use Disorder Treated with Methadone. Subst Abuse. 2016;10:9-18.

75. Jumah NA, Edwards C, Balfour-Boehm J, et al. Observational Study of the Safety of Buprenorphine+naloxone in Pregnancy in a Rural and Remote Population. BMJ Open. 2016;6(10):e011774-2016-011774.

76. The College of Physicians and Surgeons of Ontario (CPSO). Annual Report: 2014. Toronto, ON: The College of Physicians and Surgeons of Ontario (CPSO); 2014. http://www.joomag.com/magazine/annual-report/0266839001438971379?short.

77. Health Canada. Health Canada Statement on Change in Federal Prescription Status of Naloxone. Ottawa, ON: Health Canada; 2016. http://news.gc.ca/web/article-en.do?nid=1027679.

78. Ontario Public Drug Programs Division, Ministry of Health and Long-Term Care. Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP). Toronto, ON: Ministry of Health and Long-Term Care; 2016. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/not_exec_office_20160824.pdf.

79. Canadian Centre on Substance Abuse (CCSA). CCENDU Bulletin: The Availability of Take-Home Naloxone in Canada. Ottawa, ON: Canadian Centre on Substance Abuse (CCSA); 2016. http://www.ccsa.ca/Resource%20Library/CCSA-CCENDU-Take-Home-Naloxone-Canada-2016-en.pdf.

80. Health Canada. Canadian Tobacco, Alcohol and Drugs Survey (CTADS): Summary of Results for 2015. Ottawa, ON: Health Canada; 2016. http://healthycanadians.gc.ca/science-research-sciences-recherches/data-donnees/ctads-ectad/summary-sommaire-2015-eng.php.

81. Grewal R, Allen VG, Gardner S, et al. Serosorting and Recreational Drug use are Risk Factors for Diagnosis of Genital Infection with Chlamydia and Gonorrhoea among HIV-Positive Men Who have Sex with Men: Results from a Clinical Cohort in Ontario, Canada. Sex Transm Infect. 2016. doi: 10.1136/sextrans-2015-052500.

82. Fischer B, Rehm J, Patra J, et al. Crack Across Canada: Comparing Crack and Non-Crack Users in a Multi-City Cohort of Opioid and Other Street Drug Users. Addiction. 2006;101(12):1760-1770.

83. Husbands W, Lau C, Murray J, et al. Party Drugs in Toronto's Gay Dance Club Scene: Issues for HIV Prevention for Gay Men. Toronto, ON: AIDS Committee of Toronto; 2004. http://www.actoronto.org/research.nsf/cl/B85ADAFA8ADFB3F885256F480061E2D3/$file/Party%20Drugs%20Report.pdf.

84. Stoduto G, Mann RE, Ialomiteanu A, Wickens CM, Brands B. Examining the Link between Collision Involvement and Cocaine Use. Drug Alcohol Depend. 2012;123(1-3):260-263.

85. Ontario Harm Reduction Distribution Program (OHRDP). What You Told Us about Drug use in Ontario through the Drug use in Ontario Survey. Kingston, ON: Ontario Harm Reduction Distribution Program (OHRDP); 2015. http://www.ohrdp.ca/wp-content/uploads/2015/11/DrugUseInOntario-OHRDP.pdf.

86. Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. "I Inject Less as I have Easier Access to Pipes" Injecting, and Sharing of Crack-Smoking Materials, Decline as Safer Crack-Smoking Resources are Distributed. Int J Drug Policy. 2008;19(3):255-264.

87. Haydon E, Fischer B. Crack use as a Public Health Problem in Canada - Call for an Evaluation of 'Safer Crack use Kits'. Can J Public Health. 2005;96(3):185-188.

88. Patis A. Health Officials Pleased with Safe Crack Smoking Initiative. Blackburn News. . Available from: http://blackburnnews.com/london/2015/01/29/health-officials-pleased-with-safe-crack-smoking-initiative/.

89. Ontario Ministry of Health and Long Term Care (OMHLTC). 2012/13 Report Card for the Ontario Drug Benefit Program. Toronto, ON: Ontario Ministry of Health and Long Term Care (OMHLTC); 2013. http://www.health.gov.on.ca/en/public/programs/drugs/publications/opdp/docs/odb_report_13.pdf.

90. Morgan S, Smolina K, Mooney D, et al. The Canadian Rx Atlas, 3rd Edition. Vancouver, British Columbia: UBC Centre for Health Services and Policy Research; 2013.

91. Iaboni A, Bronskill SE, Reynolds KB, et al. Changing Pattern of Sedative use in Older Adults: A Population-Based Cohort Study. Drugs Aging. 2016;33(7):523-533.

92. Currie CL, Wild TC. Adolescent use of Prescription Drugs to Get High in Canada. Can J Psychiatry. 2012;57(12):745-751.

93. Steele LS, Macdonald EM, Gomes T, et al. Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. Ann Fam Med. 2015;13(4):343-346.

94. Health Canada. Summary of Results of the 2012-2013 Youth Smoking Survey. http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_survey-sondage_2012-2013/result-eng.php. Updated 2014. Accessed 01/07, 2015.

95. Millson P, Leonard L, Remis RS, Strike C, Challacombe L. Injection Drug use, HIV and HCV Infection in Ontario: The Evidence 1992 to 2004. Toronto, ON: HIV Social, Behavioral and Epidemiological Studies Unit, Ontario Harm Reduction Distribution Program (OHRDP); 2004. http://www.ohrdp.ca/wp-content/uploads/2013/03/Research_Report.pdf.

96. DeProphetis M, Nelson N, Young D, Sieswerda L, Binette D. The 2005 Thunder Bay Street Youth Drug use Questionnaire. Thunder Bay, ON: Thunder Bay District Health Unit; 2006. http://www.tbdhu.com/NR/rdonlyres/B078516B-B5E4-4C30-B57C-47AF3BF9ED0A/0/05TBStreetYouthDrugUseReport.pdf.

97. Calzavara L, Ramuscak N, Burchell AN, et al. Prevalence of HIV and Hepatitis C Virus Infections among Inmates of Ontario Remand Facilities. CMAJ. 2007;177(3):257-261.

98. Fischer B, Cruz MF, Rehm J. Illicit Opioid use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users (OPICAN). Can J Psychiatry. 2006;51(10):624-634.

99. Fischer B, Manzoni P, Rehm J. Comparing Injecting and Non-Injecting Illicit Opioid Users in a Multisite Canadian Sample (OPICAN Cohort). Eur Addict Res. 2006;12(4):230-239.

100. Firestone-Cruz M, Fischer B. A Qualitative Exploration of Prescription Opioid Injection among Street-Based Drug Users in Toronto: Behaviours, Preferences and Drug Availability. Harm Reduct J. 2008;5(1):30.

101. Firestone M, Goldman B, Fischer B. Fentanyl use among Street Drug Users in Toronto, Canada: Behavioural Dynamics and Public Health Implications. Int J Drug Policy. 2009;20(1):90-92.

102. Rotondi NK, Strike C, Kolla G, et al. Transition to Injection Drug use: The Role of Initiators. AIDS Behav. 2014;18(3):486-494.

103. Kolla G, Strike C, Roy E, et al. Initiation Stories: An Examination of the Narratives of People Who Assist with a First Injection. Subst Use Misuse. 2015;50(13):1619-1627.

104. Ontario HIV Epidemiological Monitoring Unit. HIV Update (Table 2). http://www.ohemu.utoronto.ca/doc/2013/Table%202.pdf. Updated 2013. Accessed 11/14, 2014.

105. Sullivan A, Swantee C, Rank C, et al. Race/Ethnicity of Newly Diagnosed HIV Cases in Ontario, 2009-2011 . Toronto, ON: Public Health Ontario, Public Health Agency of Canada, OHTN Research Conference Monday, November 14-15, 2011.; 2011. http://conference.ohtn.on.ca/past-conferences/2011/Presentations/138.pdf.

106. Remis RR, Liu J. Epidemiology of Hepatitis C Infection in Ontario, 2010. Toronto, ON: AIDS Bureau, Ontario Ministry of Health and Long-Term Care; 2011. http://www.ohemu.utoronto.ca/Docs/Epidemiology_of_Hepatitis_C_infection_in_Ontario.pdf. Accessed 7 October 2013.

107. Firestone Cruz M, Fischer B, Patra J, et al. Prevalence and Associated Factors of Hepatitis C Infection (HCV) in a Multi-Site Canadian Population of Illicit Opioid and Other Drug Users (OPICAN). Can J Public Health. 2007;98:130-133.

108. Ontario Harm Reduction Distribution Program (OHRDP). Needle Syringe Programs. http://www.ohrdp.ca/about-us/needle-exchange/. Updated 2016.

109. Strike C, Hopkins S, Watson TM, et al. Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Service to People Who use Drugs and are at Risk for HIV, HCV, and Other Harms. Toronto, ON: Working Group on Best Practice for Harm Reduction Programs in Canada; 2013.

110. Smith M. Toronto city council approves three downtown supervised injection sites. The Globe and Mail. July 14, 2016. Available from: http://www.theglobeandmail.com/news/toronto/toronto-city-council-approves-three-supervised-injection-sites-in-downtown-core/article30917128/.

111. CBC News. Ottawa Board of Health votes in favour of supervised drug injection sites. CBC News. June 21, 2016. Available from: http://www.cbc.ca/news/canada/ottawa/supervised-injection-ottawa-health-board-vote-1.3644921.

112. Van Dongen M. Hamilton to study possible supervised injection sites. Hamilton Spectator. . Available from: http://www.thespec.com/news-story/6866911-hamilton-to-study-possible-supervised-injection-sites/.

113. Sher J. Study probes safe injection sites for London. London Free Press. February 4, 2016. Available from: http://www.lfpress.com/2016/02/04/study-probes-safe-injection-sites.

114. Strike C, Jairam JA, Kolla G, et al. Increasing Public Support for Supervised Injection Facilities in Ontario, Canada. Addiction. 2014;109(6):946-953.

115. Strike C, Rotondi NK, Watson TM, Kolla G, Bayoumi AM. Public Opinions about Supervised Smoking Facilities for Crack Cocaine and Other Stimulants. Subst Abuse Treat Prev Policy. 2016;11:8.

116. Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential Cost-Effectiveness of Supervised Injection Facilities in Toronto and Ottawa, Canada. Addiction. 2016;111(3):475-489.

117. Shaw SY, Shah L, Jolly AM, Wylie JL. Determinants of Injection Drug User (IDU) Syringe Sharing: The Relationship between Availability of Syringes and Risk Network Member Characteristics in Winnipeg, Canada. Addiction. 2007;102(10):1626-1635.

118. Durbin J, Lin E, Zaslavska N. Impact Study Final Report. Toronto, Ontario, Canada: Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health; 2010.

119. Chiefs of Ontario. Ontario Region First Nations Addiction Service Needs Assessment: Final Report. Ottawa, Ontario: First Nations and Inuit Health Branch of Health Canada & Chiefs of Ontario; 2009.​